Cargando…

Baseline insulin sensitivity affects response to high-amylose maize resistant starch in women: a randomized, controlled trial

BACKGROUND: Resistant starch (RS) is a type of dietary fiber that can improve glucose metabolism, but its effects may be modulated by sex or baseline insulin sensitivity. This study was designed to examine the effect of high-amylose maize resistant starch (HAM-RS2) on insulin sensitivity (S(I)) in w...

Descripción completa

Detalles Bibliográficos
Autores principales: Gower, Barbara A., Bergman, Richard, Stefanovski, Darko, Darnell, Betty, Ovalle, Fernando, Fisher, Gordon, Sweatt, S. Katherine, Resuehr, Holly S., Pelkman, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711008/
https://www.ncbi.nlm.nih.gov/pubmed/26766961
http://dx.doi.org/10.1186/s12986-016-0062-5
_version_ 1782409899550965760
author Gower, Barbara A.
Bergman, Richard
Stefanovski, Darko
Darnell, Betty
Ovalle, Fernando
Fisher, Gordon
Sweatt, S. Katherine
Resuehr, Holly S.
Pelkman, Christine
author_facet Gower, Barbara A.
Bergman, Richard
Stefanovski, Darko
Darnell, Betty
Ovalle, Fernando
Fisher, Gordon
Sweatt, S. Katherine
Resuehr, Holly S.
Pelkman, Christine
author_sort Gower, Barbara A.
collection PubMed
description BACKGROUND: Resistant starch (RS) is a type of dietary fiber that can improve glucose metabolism, but its effects may be modulated by sex or baseline insulin sensitivity. This study was designed to examine the effect of high-amylose maize resistant starch (HAM-RS2) on insulin sensitivity (S(I)) in women, and to determine if S(I) status affects the response to RS. METHODS: This was a randomized, placebo-controlled, double-blind, cross-over study. Participants were 40 healthy, non-diabetic women aged 22–67 years in the normal-weight to obese BMI range (20.6–47.4 kg/m(2)). Two doses of HAM-RS2 were tested, 15 and 30 g per day, administered in the form of cookies. Participants were randomized to the order in which they received the experimental and placebo product. Each arm was 4 weeks, with a 4-week wash-out period in between. S(I) was assessed at the end of each 4-week arm of product consumption by frequently-sampled, insulin-modified, intravenous glucose tolerance test and minimal modeling. Participants were categorized as being insulin resistant (IR; S(I) < 7.8) or insulin sensitive (IS; S(I) ≥ 7.8) based on Gaussian analysis. The effect of treatment arm on S(I) was examined by mixed-model analysis within IR and IS sub-groups, using all available data. In addition, S(I) was examined by ANOVA among just those women who completed all three arms of the study with valid S(I) results. RESULTS: Among IR participants, S(I) was on average ~16 % higher after the 30 g arm when compared to the control arm by mixed-model analysis (n = 40, P < 0.05), and tended to be 23 % higher by ANOVA among women who completed all arms (n = 23, P = 0.06). HAM-RS2 did not affect S(I) in IS women. CONCLUSION: Consumption of HAM-RS2 at 30 g/day in the form of a snack food item was associated with improved insulin sensitivity in women with insulin resistance. CLINICAL TRIALS REGISTRY NUMBER: NCT0152806.
format Online
Article
Text
id pubmed-4711008
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47110082016-01-14 Baseline insulin sensitivity affects response to high-amylose maize resistant starch in women: a randomized, controlled trial Gower, Barbara A. Bergman, Richard Stefanovski, Darko Darnell, Betty Ovalle, Fernando Fisher, Gordon Sweatt, S. Katherine Resuehr, Holly S. Pelkman, Christine Nutr Metab (Lond) Research BACKGROUND: Resistant starch (RS) is a type of dietary fiber that can improve glucose metabolism, but its effects may be modulated by sex or baseline insulin sensitivity. This study was designed to examine the effect of high-amylose maize resistant starch (HAM-RS2) on insulin sensitivity (S(I)) in women, and to determine if S(I) status affects the response to RS. METHODS: This was a randomized, placebo-controlled, double-blind, cross-over study. Participants were 40 healthy, non-diabetic women aged 22–67 years in the normal-weight to obese BMI range (20.6–47.4 kg/m(2)). Two doses of HAM-RS2 were tested, 15 and 30 g per day, administered in the form of cookies. Participants were randomized to the order in which they received the experimental and placebo product. Each arm was 4 weeks, with a 4-week wash-out period in between. S(I) was assessed at the end of each 4-week arm of product consumption by frequently-sampled, insulin-modified, intravenous glucose tolerance test and minimal modeling. Participants were categorized as being insulin resistant (IR; S(I) < 7.8) or insulin sensitive (IS; S(I) ≥ 7.8) based on Gaussian analysis. The effect of treatment arm on S(I) was examined by mixed-model analysis within IR and IS sub-groups, using all available data. In addition, S(I) was examined by ANOVA among just those women who completed all three arms of the study with valid S(I) results. RESULTS: Among IR participants, S(I) was on average ~16 % higher after the 30 g arm when compared to the control arm by mixed-model analysis (n = 40, P < 0.05), and tended to be 23 % higher by ANOVA among women who completed all arms (n = 23, P = 0.06). HAM-RS2 did not affect S(I) in IS women. CONCLUSION: Consumption of HAM-RS2 at 30 g/day in the form of a snack food item was associated with improved insulin sensitivity in women with insulin resistance. CLINICAL TRIALS REGISTRY NUMBER: NCT0152806. BioMed Central 2016-01-13 /pmc/articles/PMC4711008/ /pubmed/26766961 http://dx.doi.org/10.1186/s12986-016-0062-5 Text en © Gower et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Gower, Barbara A.
Bergman, Richard
Stefanovski, Darko
Darnell, Betty
Ovalle, Fernando
Fisher, Gordon
Sweatt, S. Katherine
Resuehr, Holly S.
Pelkman, Christine
Baseline insulin sensitivity affects response to high-amylose maize resistant starch in women: a randomized, controlled trial
title Baseline insulin sensitivity affects response to high-amylose maize resistant starch in women: a randomized, controlled trial
title_full Baseline insulin sensitivity affects response to high-amylose maize resistant starch in women: a randomized, controlled trial
title_fullStr Baseline insulin sensitivity affects response to high-amylose maize resistant starch in women: a randomized, controlled trial
title_full_unstemmed Baseline insulin sensitivity affects response to high-amylose maize resistant starch in women: a randomized, controlled trial
title_short Baseline insulin sensitivity affects response to high-amylose maize resistant starch in women: a randomized, controlled trial
title_sort baseline insulin sensitivity affects response to high-amylose maize resistant starch in women: a randomized, controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711008/
https://www.ncbi.nlm.nih.gov/pubmed/26766961
http://dx.doi.org/10.1186/s12986-016-0062-5
work_keys_str_mv AT gowerbarbaraa baselineinsulinsensitivityaffectsresponsetohighamylosemaizeresistantstarchinwomenarandomizedcontrolledtrial
AT bergmanrichard baselineinsulinsensitivityaffectsresponsetohighamylosemaizeresistantstarchinwomenarandomizedcontrolledtrial
AT stefanovskidarko baselineinsulinsensitivityaffectsresponsetohighamylosemaizeresistantstarchinwomenarandomizedcontrolledtrial
AT darnellbetty baselineinsulinsensitivityaffectsresponsetohighamylosemaizeresistantstarchinwomenarandomizedcontrolledtrial
AT ovallefernando baselineinsulinsensitivityaffectsresponsetohighamylosemaizeresistantstarchinwomenarandomizedcontrolledtrial
AT fishergordon baselineinsulinsensitivityaffectsresponsetohighamylosemaizeresistantstarchinwomenarandomizedcontrolledtrial
AT sweattskatherine baselineinsulinsensitivityaffectsresponsetohighamylosemaizeresistantstarchinwomenarandomizedcontrolledtrial
AT resuehrhollys baselineinsulinsensitivityaffectsresponsetohighamylosemaizeresistantstarchinwomenarandomizedcontrolledtrial
AT pelkmanchristine baselineinsulinsensitivityaffectsresponsetohighamylosemaizeresistantstarchinwomenarandomizedcontrolledtrial